Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Lundbeck

Tracked across 11 events · 71 articles · First seen Apr 13, 2026 · Last active Sep 22, 2026

Sentiment
38
Attention
4
Events
11
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 20
Tech
Impact: Lundbeck is presenting new data across its neurology portfolio, including bocunebart, eptinezumab, and bexicaserin, at the American Academy of Neurology Annual Meeting 2026, highlighting its commitment to advancing brain disease treatments.
Apr 13, 2026 · 6 articles
4 70
Business
Impact: Lundbeck received orphan drug designation in Japan for asedebart, which is a positive development for the company's pipeline and market reach in rare diseases.
May 18, 2026 · 7 articles
4 70
Business
Impact: Lundbeck received marketing authorization for its migraine treatment, eptinezumab, in South Korea, expanding its global market presence and potential revenue.
May 26, 2026 · 7 articles
4 70
Tech
Impact: Lundbeck announced positive preliminary Phase II Part A data for asedebart in Cushing's disease, which is encouraging for its drug development pipeline and future market position in rare endocrine disorders.
Jun 14, 2026 · 6 articles
3 40
Business
Impact: Lundbeck achieved a key enrollment milestone for its lead pipeline asset bexicaserin, advancing toward potential approval in DEEs.
Jul 20, 2026 · 6 articles
2 20
Regulatory
Impact: Lundbeck received FDA Fast Track designation for its lead orexin 2 receptor agonist, Lu AH69593, for narcolepsy. This regulatory milestone supports its R&D pipeline and may expedite development.
Jul 23, 2026 · 6 articles
4 70
Business
Impact: Core entity reporting strong H1 2026 results with revenue and earnings growth, pipeline advancements, and strategic partnerships, positively impacting its financial position and market perception.
Jul 20, 2026 · 7 articles
2 10
Business
Impact: Lundbeck is the target of the exchange offer, with its A-shares being exchanged. The company's participation indicates support for the offer, which may affect its shareholder base and governance.
Aug 19, 2026 · 6 articles
2 20
Regulatory
On August 24, 2026, the International — European Commission granted orphan designation to Lundbeck's investigational anti-ACTH monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing's syndrome of endogenous origin. This designation supports development of…
Impact: Lundbeck received the orphan designation for its investigational drug asedebart, enhancing its rare disease pipeline and potential market exclusivity. This regulatory milestone supports its strategic focus on neuroendocrine and rare disorders.
Aug 24, 2026 · 6 articles
2 25
Regulatory
Lundbeck announced on September 16, 2026 that Japan's Bangladesh — Ministry of Health and Family Welfare granted marketing authorization for Vyepti (eptinezumab) for the prevention of migraine attacks in adults. Eptinezumab is a humanized monoclonal…
Impact: Lundbeck receives Japanese marketing authorization for Vyepti, enabling its first independent launch in Japan and expanding its migraine franchise into a new major market.
Sep 16, 2026 · 8 articles
2 5
Business
Iambic Therapeutics, a San Diego-based drug developer backed by Nvidia and the Qatar Investment Authority, filed for a US initial public offering on Monday, September 21, 2026, aiming to list on the Nasdaq under the…
Impact: Listed as an existing partnership partner of Iambic, with no new action in this event.
Sep 21, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Lundbeck live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.